ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Inclusion Criteria 1. Age \>/= 18 years. 2. Rheumatoid arthritis for \>/= 6 months. 3. Active disease as defined by \>/= 6 swollen and \>/= 9 tender joints, AND an abnormal C-reactive protein or Westergren Erythrocyte Sedimentation Rate lab test, OR Morning Stiffness \>/= 1 hour. 4. Use of at least one DMARD, and ability to discontinue any current DMARD. Exclusion Criteria 1. Onset of rheumatoid arthritis before the 16th birthday. 2. Wheelchair or bed-bound functional level. 3. No previous infliximab or etanercept treatment, or investigational therapy (not placebo) with other TNF-alpha inhibitors. 4. Prednisone \> 10 mg per day or more than one nonsteroidal anti-inflammatory drug. 5. Patients with an active infection, a history of tuberculosis, multiple sclerosis, other poorly controlled medical illness, or a malignancy within the last 5 years. 6. Patients who require intravenous heparin therapy or with a history of a bleeding problem.